<DOC>
	<DOCNO>NCT00786838</DOCNO>
	<brief_summary>The purpose study assess potential effect trabectedin QT/QTc interval duration measure electrocardiogram ( ECGs ) participant advance solid tumor malignancy administer therapeutic dose .</brief_summary>
	<brief_title>A Study Assess Potential Effects Single-Dose Administration Trabectedin QT Intervals Electrocardiogram</brief_title>
	<detailed_description>This single-blind ( participant know treatment receives ) , multicenter ( study conduct multiple site ) , placebo-controlled ( inactive substance compare study medication test whether study medication real effect clinical study ) , sequential design ( design single group Participants one study medication administer sequence ) study evaluate potential effect single-dose administration trabectedin QT interval electrocardiogram ( ECG ) . Initially , study consist 2 phase : screening phase ( within 21 day administration study medication ) , single-blind treatment phase ( 2 day ) . Participants complete single-blind treatment phase opt take trabectedin open-label extension ( minimum 6 cycle ) , long derive clinical benefit ( ie , clear evidence disease progression unacceptable toxicity , judge investigator ) . Participants assess ECG predose single-blind treatment phase . During single-blind treatment phase , placebo control give Day 1 , trabectedin ( 1.3 mg per square meter ) administer Day 2 . Participants monitor completion 24 hour pharmacokinetic blood sample collection . During open-label extension ( 21 day completion single-blind treatment phase ) , Participants receive trabectedin intravenously Day 1 17- 49 day treatment cycle . The dose schedule trabectedin modify accord type malignancy treat ( ie , sarcoma , ovarian , breast cancer ) . Safety evaluation include assessment adverse event , vital sign , physical examination , clinical laboratory test perform throughout study . The study duration open-label extension vary participant .</detailed_description>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Participants locally advance metastatic solid tumor receive three less prior line systemic chemotherapy Participants must relapse progressive disease follow standard care treatment chemotherapy prior enrollment , intolerant prior standard care treatment chemotherapy Normal cardiac conduction function document 12lead electrocardiogram Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Adequate organ function evidence laboratory test Able receive dexamethasone equivalent Agrees protocoldefined use effective contraception Participants treat three prior chemotherapy regimen ( include adjuvant therapy ) Previous exposure trabectedin Central nervous system ( CNS ) metastasis Known hypersensitivity component trabectedin intravenous formulation dexamethasone Heart rhythm disturbance , unusual T wave U wave ( present ) morphology , blood pressure outside normal range , history cardiac failure , myocardial infarction , cardiomyopathy , history additional risk factor torsade de pointes ( eg , heart failure , electrolyte abnormality , family history Long QT Syndrome ) Participants screen medication know prolong QT interval CYP3A4 inhibitor inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Malignant tumor</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Breast tumor</keyword>
	<keyword>Ovarian tumor</keyword>
	<keyword>QT interval</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>Yondelis</keyword>
	<keyword>Ecteinascidin 743</keyword>
	<keyword>ET743</keyword>
</DOC>